Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

QOL Concerns Prompt Second-Line Therapy in ITP

Key clinical point: Quality of life was the most frequently cited reason for starting second-line therapy in children with immune thrombocytopenia.

Major finding: Quality of life was chosen as a reason to treat in 73% of patients, it was among the top three reasons in 57% of patients, and it was the most important reason in 27%.

Study details: A survey of hematologists treating 120 children in an observational study.

Disclosures: The speaker reported involvement in an investigator-initiated trial for eltrombopag in children with ITP. The study, which has not yet opened, is funded by Novartis.


Shimano KA et al. ASPHO 2019, Abstract 2012.